DDInter1961 DDInter1657
A dideoxynucleoside compound in which the 3&#39;-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with [bortezomib] and [dexamethasone], is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells.[L7117,L7120,L10145] This condition is typically treated with high dose [bortezomib] and [dexamethasone] chemotherapy followed by an autologous stem-cell transplant. Other chemotherapies for multiple myeloma include [lenalidomide] and [dexamethasone], [thalidomide], and may include [melphalan] if the patient is not eligible for transplant. Selinexor was also granted accelerated approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that have gone through at least 2 lines of systemic therapy. The FDA approved Selinexor in June 2019. The use of selinexor in combination with [bortezomib] and [dexamethasone] was approved by Health Canada in June 2022 for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.
Zidovudine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trifluridine
Zidovudine {u} (Compound) resembles {v} (Compound) Idoxuridine
Zidovudine {u} (Compound) resembles {v} (Compound) Telbivudine
Zidovudine {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
Zidovudine {u} (Compound) binds {v} (Gene) UGT2B7
Zidovudine {u} (Compound) upregulates {v} (Gene) THAP11
Zidovudine {u} (Compound) is included by {v} (Pharmacologic Class) Nucleoside Reverse Transcriptase Inhibitors
Zidovudine {u} (Compound) downregulates {v} (Gene) MRPS16
Zidovudine {u} (Compound) causes {v} (Side Effect) Tremor
Zidovudine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Trifluridine
Zidovudine (Compound) resembles Idoxuridine (Compound)
Zidovudine (Compound) resembles Telbivudine (Compound)
Zidovudine (Compound) treats acquired immunodeficiency syndrome (Disease)
Zidovudine (Compound) binds UGT2B7 (Gene)
Zidovudine (Compound) upregulates THAP11 (Gene)
Zidovudine (Compound) is included by Nucleoside Reverse Transcriptase Inhibitors (Pharmacologic Class)
Zidovudine (Compound) downregulates MRPS16 (Gene)
Zidovudine (Compound) causes Tremor (Side Effect)
Zidovudine may cause a minor interaction that can limit clinical effects when taken with Cimetidine